Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.43 |
| ▸ | AKT2 | P31751 | 16/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707946 | 0.86 | AKT1 (0.44) | AKT1AKT2USP30CCR1CCR8 | |
| Hydrochloric Acid SCHEMBL3708885 | 0.84 | AKT1 (0.43) | AKT1AKT2USP30CCR1CCR8 | |
| SCHEMBL10286741 | 0.79 | USP30 (0.59) | AKT1AKT2USP30 | |
| SCHEMBL1428337 | 0.76 | CCR1 (0.42) | CCR1CCR8 | |
| SCHEMBL2755247 | 0.76 | CCR1 (0.42) | TLR9TLR8TLR7CCR1CCR8 | |
| SCHEMBL3701974 | 0.76 | AKT1 (0.48) | AKT1AKT2USP30 | |
| Hydrochloric Acid SCHEMBL15310330 | 0.75 | CCR1 (0.41) | CCR1CCR8 | |
| SCHEMBL10070058 | 0.75 | USP30 (0.56) | USP30TLR9TLR8TLR7 | |
| SCHEMBL12093290 | 0.74 | HTR2C (0.47) | TLR9TLR8TLR7CCR1CCR8 | |
| SCHEMBL30469416 | 0.74 | HTR2C (0.47) | TLR9TLR8TLR7CCR1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614218-B2 | Fused bicyclic pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| CN-101778851-B | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG | 2013-05-08 | — | — | CN | disclosed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | disclosed |
| US-7776864-B2 | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| CN-101778851-A | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG | 2010-07-14 | — | — | CN | disclosed |
| EP-2188291-A2 | FUSED BICYCLIC PYRIMIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-05-26 | — | — | EP | disclosed |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| WO-2009021992-A2 | FUSED BICYCLIC PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | AKT1 9/4885AKT2 4/4885USP30 4526/4885 |
| US-20100184782-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | AKT1 9/4885AKT2 4/4885USP30 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.